Roche Holding (SWX:ROG) has been quietly rewarding patient shareholders, with the stock gaining about 12% over the past month and roughly 25% year to date, outpacing many large pharma peers.
See our latest analysis for Roche Holding.
That kind of steady upward move, with a roughly 25% year to date share price return and a one year total shareholder return near 30%, suggests momentum is quietly building as investors reassess Roche’s growth and pipeline risks.
If Roche’s run has you looking across healthcare, it is a good moment to scout other potential leaders using our curated screen of healthcare stocks.
With the shares now hovering near analyst targets but still trading at a steep discount to some intrinsic value models, investors face a key question: is this a compelling entry point, or is future growth already fully priced in?
With Roche Holding last closing at CHF 321.90 against a narrative fair value near CHF 312, the latest consensus frames the upside as finely balanced rather than explosive.
Analysts expect the number of shares outstanding to grow by 0.12% per year for the next 3 years. To value all of this in today’s terms, we will use a discount rate of 3.82%, as per the Simply Wall St company report.
Want to see how modest revenue growth, expanding margins, and a lower future earnings multiple can still support this valuation? The narrative walks through a surprisingly tight set of assumptions, and how they add up to today’s fair value call.
Result: Fair Value of $312 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, several risks, including China pricing reforms and looming biosimilar competition on key biologics, could quickly undermine today’s carefully balanced valuation narrative.
Find out about the key risks to this Roche Holding narrative.
While the narrative fair value of around CHF 312 suggests Roche is modestly overvalued, our DCF model paints a very different picture, implying shares trade at roughly a 56% discount to intrinsic value. When models disagree this sharply, which set of assumptions would you trust in a downturn?
Look into how the SWS DCF model arrives at its fair value.
ROG Discounted Cash Flow as at Dec 2025
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Roche Holding for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 906 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.
If you see Roche’s story differently, or simply want to test your own assumptions against the numbers, you can craft a custom view in minutes, Do it your way.
A great starting point for your Roche Holding research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
Before you move on, lock in your edge by scanning targeted stock ideas on Simply Wall Street’s screener so you do not miss the next standout performer.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROG.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com